Advancing Treatment for Friedreich’s Ataxia There is promising news for the Friedreich’s ataxia community. Graviton Bioscience recently announced that its therapeutic candidate, GV101, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA). What is Fast Track Designation? The FDA’s Fast Track program is designed to facilitate the development and expedite…